208 related articles for article (PubMed ID: 24357345)
1. Investigation of the therapeutic efficacy of codelivery of psiRNA-vascular endothelial growth factor and pIL-4 into chitosan nanoparticles in the breast tumor model.
Şalva E; Turan SO; Kabasakal L; Alan S; Özkan N; Eren F; Akbuğa J
J Pharm Sci; 2014 Mar; 103(3):785-95. PubMed ID: 24357345
[TBL] [Abstract][Full Text] [Related]
2. Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles.
Feng Q; Yu MZ; Wang JC; Hou WJ; Gao LY; Ma XF; Pei XW; Niu YJ; Liu XY; Qiu C; Pang WH; Du LL; Zhang Q
Biomaterials; 2014 Jun; 35(18):5028-38. PubMed ID: 24680191
[TBL] [Abstract][Full Text] [Related]
3. A study of the suppressive effect on human pancreatic adenocarcinoma cell proliferation and angiogenesis by stable plasmid-based siRNA silencing of c-Src gene expression.
Zhao X; Li DC; Zhao H; Li Z; Wang JX; Zhu DM; Zhou J; Cen JN
Oncol Rep; 2012 Mar; 27(3):628-36. PubMed ID: 22200682
[TBL] [Abstract][Full Text] [Related]
4. Local delivery of chitosan/VEGF siRNA nanoplexes reduces angiogenesis and growth of breast cancer in vivo.
Salva E; Kabasakal L; Eren F; Ozkan N; Cakalağaoğlu F; Akbuğa J
Nucleic Acid Ther; 2012 Feb; 22(1):40-8. PubMed ID: 22217324
[TBL] [Abstract][Full Text] [Related]
5. Nanocomposite-siRNA approach for down-regulation of VEGF and its receptor in myeloid leukemia cells.
Wang L; Zhang WJ; Xiu B; Ding Y; Li P; Ye WD; Zhu Q; Liang AB
Int J Biol Macromol; 2014 Feb; 63():49-55. PubMed ID: 24183807
[TBL] [Abstract][Full Text] [Related]
6. Chitosan/short hairpin RNA complexes for vascular endothelial growth factor suppression invasive breast carcinoma.
Salva E; Kabasakal L; Eren F; Cakalağaoğlu F; Ozkan N; Akbuğa J
Oligonucleotides; 2010 Aug; 20(4):183-90. PubMed ID: 20707740
[TBL] [Abstract][Full Text] [Related]
7. In vitro silencing effect of chitosan nanoplexes containing siRNA expressing vector targeting VEGF in breast cancer cell lines.
Salva E; Akbuğa J
Pharmazie; 2010 Dec; 65(12):896-902. PubMed ID: 21284259
[TBL] [Abstract][Full Text] [Related]
8. Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells.
Song Y; Tang C; Yin C
Biomaterials; 2018 Dec; 185():117-132. PubMed ID: 30241030
[TBL] [Abstract][Full Text] [Related]
9. The enhancement of gene silencing efficiency with chitosan-coated liposome formulations of siRNAs targeting HIF-1α and VEGF.
Şalva E; Turan SÖ; Eren F; Akbuğa J
Int J Pharm; 2015 Jan; 478(1):147-154. PubMed ID: 25445537
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with short interfering RNA vectors against VEGF-C and VEGF-A suppresses lymph node and lung metastasis in a mouse immunocompetent mammary cancer model.
Shibata MA; Morimoto J; Shibata E; Otsuki Y
Cancer Gene Ther; 2008 Dec; 15(12):776-86. PubMed ID: 18654613
[TBL] [Abstract][Full Text] [Related]
11. Direct cytosolic siRNA delivery by reconstituted high density lipoprotein for target-specific therapy of tumor angiogenesis.
Ding Y; Wang Y; Zhou J; Gu X; Wang W; Liu C; Bao X; Wang C; Li Y; Zhang Q
Biomaterials; 2014 Aug; 35(25):7214-27. PubMed ID: 24875759
[TBL] [Abstract][Full Text] [Related]
12. Comparison of VEGF gene silencing efficiencies of chitosan and protamine complexes containing shRNA.
Erdem-Çakmak F; Özbaş-Turan S; Şalva E; Akbuğa J
Cell Biol Int; 2014 Nov; 38(11):1260-70. PubMed ID: 24890139
[TBL] [Abstract][Full Text] [Related]
13. VEGF siRNA delivered by polycation liposome-encapsulated calcium phosphate nanoparticles for tumor angiogenesis inhibition in breast cancer.
Chen J; Sun X; Shao R; Xu Y; Gao J; Liang W
Int J Nanomedicine; 2017; 12():6075-6088. PubMed ID: 28860767
[TBL] [Abstract][Full Text] [Related]
14. Co-delivery of VEGF siRNA and Etoposide for Enhanced Anti-angiogenesis and Anti-proliferation Effect
Li F; Wang Y; Chen WL; Wang DD; Zhou YJ; You BG; Liu Y; Qu CX; Yang SD; Chen MT; Zhang XN
Theranostics; 2019; 9(20):5886-5898. PubMed ID: 31534526
[TBL] [Abstract][Full Text] [Related]
15. Lentivirus-mediated shRNA interference targeting vascular endothelial growth factor inhibits angiogenesis and progression of human pancreatic carcinoma.
Zhao X; Zhu DM; Gan WJ; Li Z; Zhang JL; Zhao H; Zhou J; Li DC
Oncol Rep; 2013 Mar; 29(3):1019-26. PubMed ID: 23254994
[TBL] [Abstract][Full Text] [Related]
16. Anti-angiogenic effects of ribonucleic acid interference targeting vascular endothelial growth factor and hypoxia-inducible factor-1alpha.
Forooghian F; Das B
Am J Ophthalmol; 2007 Nov; 144(5):761-8. PubMed ID: 17869204
[TBL] [Abstract][Full Text] [Related]
17. Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance.
Yhee JY; Song S; Lee SJ; Park SG; Kim KS; Kim MG; Son S; Koo H; Kwon IC; Jeong JH; Jeong SY; Kim SH; Kim K
J Control Release; 2015 Jan; 198():1-9. PubMed ID: 25481438
[TBL] [Abstract][Full Text] [Related]
18. Oral delivery of shRNA and siRNA via multifunctional polymeric nanoparticles for synergistic cancer therapy.
Han L; Tang C; Yin C
Biomaterials; 2014 May; 35(15):4589-600. PubMed ID: 24613049
[TBL] [Abstract][Full Text] [Related]
19. Systemic delivery of siRNA by T7 peptide modified core-shell nanoparticles for targeted therapy of breast cancer.
Yu MZ; Pang WH; Yang T; Wang JC; Wei L; Qiu C; Wu YF; Liu WZ; Wei W; Guo XY; Zhang Q
Eur J Pharm Sci; 2016 Sep; 92():39-48. PubMed ID: 27355138
[TBL] [Abstract][Full Text] [Related]
20. Co-delivery of VEGF and Bcl-2 dual-targeted siRNA polymer using a single nanoparticle for synergistic anti-cancer effects in vivo.
Lee SJ; Yook S; Yhee JY; Yoon HY; Kim MG; Ku SH; Kim SH; Park JH; Jeong JH; Kwon IC; Lee S; Lee H; Kim K
J Control Release; 2015 Dec; 220(Pt B):631-41. PubMed ID: 26307351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
